JP2014508759A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508759A5 JP2014508759A5 JP2013554892A JP2013554892A JP2014508759A5 JP 2014508759 A5 JP2014508759 A5 JP 2014508759A5 JP 2013554892 A JP2013554892 A JP 2013554892A JP 2013554892 A JP2013554892 A JP 2013554892A JP 2014508759 A5 JP2014508759 A5 JP 2014508759A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- galactosyltransferase
- domain
- sialyltransferase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305200.5 | 2011-02-24 | ||
| EP11305200 | 2011-02-24 | ||
| EP11306090 | 2011-09-01 | ||
| EP11306090.9 | 2011-09-01 | ||
| PCT/EP2012/053065 WO2012113863A1 (en) | 2011-02-24 | 2012-02-23 | Method of production of sialylated antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014508759A JP2014508759A (ja) | 2014-04-10 |
| JP2014508759A5 true JP2014508759A5 (enExample) | 2015-02-19 |
Family
ID=45774189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013554892A Pending JP2014508759A (ja) | 2011-02-24 | 2012-02-23 | シアリル化抗体の生産の方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140046032A1 (enExample) |
| EP (1) | EP2678357A1 (enExample) |
| JP (1) | JP2014508759A (enExample) |
| AR (1) | AR085302A1 (enExample) |
| TW (1) | TW201241182A (enExample) |
| WO (1) | WO2012113863A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| EP2877589B1 (en) | 2012-07-26 | 2024-03-06 | Momenta Pharmaceuticals, Inc. | Glycoproteins with anti-inflammatory properties |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| RU2711935C2 (ru) | 2013-03-11 | 2020-01-23 | Джензим Корпорейшн | Сайт-специфическая конъюгация антитело-лекарственное средство посредством гликоинженерии |
| SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| EP2855533A4 (en) | 2013-03-15 | 2015-11-25 | Momenta Pharmaceuticals Inc | METHODS RELATING TO CTLA4-FC FUSION PROTEINS |
| EP2991666B1 (en) | 2013-05-02 | 2020-03-25 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| US10464996B2 (en) | 2013-05-13 | 2019-11-05 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| JP6594860B2 (ja) * | 2013-05-29 | 2019-10-23 | エフ．ホフマン−ラ ロシュ アーゲー | シアル酸付加の定量的調節 |
| EP3017057B1 (en) | 2013-07-05 | 2019-10-02 | F.Hoffmann-La Roche Ag | Process for the mono- and bi-sialylation of glycoproteins employing n-terminally truncated beta-galactoside alpha-2,6-sialyltransferase mutants |
| EP2824176A1 (en) | 2013-07-11 | 2015-01-14 | Siamed'xpress | Methods for producing sialylated therapeutic proteins |
| EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| WO2015057622A1 (en) * | 2013-10-16 | 2015-04-23 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| PL3129067T3 (pl) | 2014-03-19 | 2023-05-08 | Genzyme Corporation | Specyficzne dla miejsca glikomodyfikowanie ugrupowań celujących |
| AU2015293949B2 (en) | 2014-07-21 | 2019-07-25 | Teknologian Tutkimuskeskus Vtt Oy | Production of glycoproteins with mammalian-like N-glycans in filamentous fungi |
| EP3037527A1 (en) * | 2014-12-22 | 2016-06-29 | F. Hoffmann-La Roche AG | Sialyltransferase without CMP-dependent sialidase activity |
| CN107429237B (zh) | 2014-12-22 | 2021-09-28 | 豪夫迈·罗氏有限公司 | Cmp依赖性的唾液酸酶活性 |
| EP3544612A4 (en) | 2016-11-23 | 2020-05-13 | Acetylon Pharmaceuticals, Inc. | PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME |
| EP3354278A1 (en) * | 2017-01-31 | 2018-08-01 | Sanofi | Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide |
| FR3080376B1 (fr) * | 2018-04-20 | 2022-12-09 | Lab Francais Du Fractionnement | Autoanticorps hautement sialyles et leurs utilisations |
| MA55529A (fr) | 2019-04-03 | 2022-02-09 | Genzyme Corp | Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| TW202325853A (zh) * | 2021-11-09 | 2023-07-01 | 美商安進公司 | 治療性蛋白之生產 |
| WO2025101901A1 (en) * | 2023-11-10 | 2025-05-15 | The Board Of Trustees Of The Leland Stanford Junior University | Use of sialylated ivig or igg fc region-containing protein for preventing or treating respiratory virus diseases |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US5474896A (en) | 1992-05-05 | 1995-12-12 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5830729A (en) | 1996-04-18 | 1998-11-03 | Institut Pasteur | I Sce I-induced gene replacement and gene conversion in embryonic stem cells |
| US20020045207A1 (en) * | 1997-10-31 | 2002-04-18 | Lynne A. Krummen | Glycoprotein production process |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2082749A3 (en) | 2000-07-07 | 2010-06-30 | Bioarctic Neuroscience AB | Prevention and treatment of Alzheimer's disease |
| EP1427828B1 (en) | 2001-09-14 | 2010-04-28 | Cellectis | Random integration of a polynucleotide after in vivo linearization |
| AU2004208031B2 (en) | 2003-01-28 | 2009-10-08 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof. |
| WO2007005786A2 (en) * | 2005-06-30 | 2007-01-11 | Centocor, Inc. | Methods and compositions with enhanced therapeutic activity |
| ATE536373T1 (de) | 2005-10-21 | 2011-12-15 | Genzyme Corp | Therapiemittel auf antikörperbasis mit erhöhter adcc-aktivität |
| US20080206246A1 (en) | 2006-04-05 | 2008-08-28 | Ravetch Jeffrey V | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| WO2008057634A2 (en) | 2006-10-26 | 2008-05-15 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| MX2008007477A (es) | 2005-12-12 | 2008-09-03 | Ac Immune Sa | Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas. |
| EP2815768A3 (en) | 2006-04-05 | 2015-01-14 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| JP2010512306A (ja) * | 2006-10-27 | 2010-04-22 | ザ ロックフェラー ユニバーシティー | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| AR063975A1 (es) * | 2006-11-28 | 2009-03-04 | Centelion | Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada |
| PE20090993A1 (es) | 2007-08-29 | 2009-07-08 | Sanofi Aventis | Anticuerpos anti-cxcr5 humanizados y derivados de los mismos |
| EP2650308A3 (en) | 2007-10-05 | 2014-11-12 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| JP2011500059A (ja) | 2007-10-15 | 2011-01-06 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ヒト抗アミロイド抗体、組成物、方法及び使用 |
| WO2009054537A1 (ja) | 2007-10-25 | 2009-04-30 | Kagoshima University | アミロイドβペプチドのミミック分子を用いたペプチドワクチン |
| AU2008317354B2 (en) | 2007-10-25 | 2014-04-10 | Ospedale San Raffaele S.R.L. | Methods and compositions for targeted integration |
| CN104098695B (zh) | 2007-10-29 | 2018-09-07 | 道健康生活医药株式会社 | 抗体及其应用 |
| EP2207568B1 (en) | 2007-11-16 | 2017-05-31 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| EP2222705B1 (en) | 2007-12-11 | 2014-10-22 | Glaxo Group Limited | Antigen binding proteins |
| EP2233502A1 (en) | 2009-03-27 | 2010-09-29 | Deutsches Rheuma-Forschungszentrum Berlin | Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them |
| FR2945538B1 (fr) * | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| US10087236B2 (en) * | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
-
2012
- 2012-02-22 AR ARP120100573A patent/AR085302A1/es unknown
- 2012-02-23 EP EP12706541.5A patent/EP2678357A1/en not_active Withdrawn
- 2012-02-23 TW TW101106076A patent/TW201241182A/zh unknown
- 2012-02-23 JP JP2013554892A patent/JP2014508759A/ja active Pending
- 2012-02-23 US US14/000,035 patent/US20140046032A1/en not_active Abandoned
- 2012-02-23 WO PCT/EP2012/053065 patent/WO2012113863A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gunn et al. | A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus | |
| JP6932693B2 (ja) | カッパ及びラムダ軽鎖を含む抗原結合ポリペプチド構築物及びその使用 | |
| TW200925273A (en) | Antibody constant region mutant | |
| TW201241182A (en) | Method of production of sialylated antibodies | |
| JP2010538608A5 (enExample) | ||
| JP2018085988A5 (enExample) | ||
| JP2021518140A5 (enExample) | ||
| TWI820484B (zh) | 抗hla-dq2.5抗體及其用於治療乳糜瀉的用途 | |
| CN105531289B (zh) | 抗cd83抗体及其用途 | |
| TWI778000B (zh) | 於活體外進行抗體糖基化工程之酶之再利用 | |
| JP2016511277A5 (enExample) | ||
| JP2012531922A5 (ja) | Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位 | |
| JP2016512425A5 (enExample) | ||
| TWI781973B (zh) | 用於以活體外進行抗體糖基化工程之方法 | |
| WO2010109010A1 (en) | Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them | |
| JP2015502915A (ja) | ＣＤ１ｄに対する抗体 | |
| CN107531794A (zh) | 具有改变的功能活性的Fc突变体 | |
| US20230073926A1 (en) | Highly sialylated multimeric binding molecules | |
| US20220306760A1 (en) | Igm glycovariants | |
| EP3108004B1 (en) | Methods to produce single glycoform antibodies | |
| JP2018537117A5 (enExample) | ||
| CN118475614A (zh) | 具有增强的效应子功能的生物合成双互补位或双特异性结合分子 | |
| CA3235999A1 (en) | Biosynthetic monovalent binding molecules with enhanced effector functions | |
| US12421305B2 (en) | Antibody for enrichment of cells | |
| TW202333781A (zh) | 抗ｈｌａ－ｄｑ２﹒５抗體製劑 |